

Concise synthesis and anti-HIV activity of pyrimido[1,2-*c*][1,3]benzothiazin-6-imines and related tricyclic heterocycles

Tsukasa Mizuhara,^a Shinya Oishi,^{*a} Hiroaki Ohno,^a Kazuya Shimura,^b Masao Matsuoka^b and Nobutaka Fujii^{*a}

^a Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan

Tel: +81-75-753-4561; Fax: +81-75-753-4570

E-mail: soishi@pharm.kyoto-u.ac.jp; nfujii@pharm.kyoto-u.ac.jp

^b Institute for Virus Research, Kyoto University, Sakyo-ku, Kyoto, 606-8507, Japan

Abstract: 3,4-Dihydro-2*H*,6*H*-pyrimido[1,2-*c*][1,3]benzothiazin-6-imine (PD 404182) is a virucidal heterocyclic compound active against various viruses, including HCV, HIV, and simian immunodeficiency virus. Using facile synthetic approaches that we developed for the synthesis of pyrimido[1,2-*c*][1,3]benzothiazin-6-imines and related tricyclic derivatives, the parallel structural optimizations of the central 1,3-thiazin-2-imine core, the benzene part, and the cyclic amidine part of PD 404182 were investigated. Replacement of the 6-6-6 pyrimido[1,2-*c*][1,3]benzothiazin-6-imine framework with 5-6-6 or 6-6-5 derivatives led to a significant loss of anti-HIV activity, and introduction of a hydrophobic group at the 9- or 10-positions improved the potency. In addition, we demonstrated that the PD 404182 derivative exerts anti-HIV effects at an early stage of viral infection.

Introduction

Since azidothymidine (AZT), a nucleoside reverse transcriptase inhibitor (NRTI), was approved for the treatment of HIV infections, a number of anti-HIV drugs have been launched. For example, saquinavir and nevirapine were the first protease inhibitor and non-nucleoside reverse transcriptase inhibitor (NNRTI), respectively.¹ Highly active antiretroviral therapy (HAART) using a combination of these antiretrovirals is a standard treatment regimen for HIV infections. The HAART regimen significantly reduces viral load in infected patients, leading to significant therapeutic gains and reductions in morbidity and mortality.² However, long-term administration of multiple antiretrovirals to maintain life-long latent infection triggers the emergence of drug-resistant variants³ and drug-related adverse effects.⁴ For example, high-level viral resistance to NRTI such as AZT, stavudine, and didanosine is conferred by mutations frequently observed in patients with virologic failure on an NRTI-containing regimen.⁵ In addition, lipodystrophy and metabolic disorders are often observed in patients receiving HIV protease inhibitors.⁶ To overcome these problems, several antiretrovirals with new mechanisms of action have been developed in this decade. A peptide-based fusion inhibitor (enfuvirtide),⁷ an integrase inhibitor (raltegravir),⁸ and a CC chemokine receptor type 5 (CCR5) antagonist (maraviroc)⁹ are examples of new molecular entities used as anti-HIV agents.

Recently, highly potent small-molecule anti-HIV agents have been reported, which bind to viral envelope proteins (Figure 1). 2-Thioxo-1,3-thiazolidine derivative **1** shows potent inhibition of HIV-1 replication at nanomolar levels,¹⁰ which are directed at the deep hydrophobic pocket in the N-terminal heptad repeat trimer of the viral gp41. Compound **1** blocks HIV-1-mediated cell–cell fusion and the formation of gp41 six-helix bundles, as does enfuvirtide.^{10b} The bisindole derivative **2** also exhibits submicromolar inhibition of HIV-1 replication by interaction with the gp41 hydrophobic pocket in which compound **1** binds.¹¹ Small-molecule CD4 mimics with oxalamide and related substructures are another series of anti-HIV agents.¹² The representative BMS-448043 (**3**) exhibits subnanomolar anti-HIV activity by interaction with the CD4 binding pocket in gp120.^{12d} These small-molecule entry inhibitors with potential oral bioavailability will provide alternative

combination regimen(s) of anti-HIV agents for the treatment of drug-resistant variants.

In our efforts to develop novel anti-HIV compounds,¹³ we have carried out the random screening of small molecules using multinuclear activation of a galactosidase indicator (MAGI) assay, in which the inhibitory activity of early-stage HIV infection, including virus attachment and membrane fusion to host cells, is evaluated. Among more than 30,000 compounds screened, 3,4-dihydro-2*H*,6*H*-pyrimido[1,2-*c*][1,3]benzothiazin-6-imine **4** (PD 404182) was identified as a potent anti-HIV agent lead (Figure 1). Compound **4** was reported to be an enzyme inhibitor against 3-deoxy-D-manno-octulosonic acid 8-phosphate synthase¹⁴ and phosphopantetheinyl transferase,¹⁵ exerting antimicrobial effects. In the course of our SAR investigations in this study, antiviral activities of **4** against HCV, HIV, and simian immunodeficiency virus were reported.^{16,17} Although compound **4** exhibits virucidal effects at high concentrations, the mechanism of action and the target molecule remain ambiguous.¹⁷

Recently, we have established two independent approaches for the synthesis of PD 404182 derivatives (Scheme 1): C–H functionalization of 2-phenyl-1,4,5,6-tetrahydropyrimidine with water or *t*-butylcarbamate in the presence of copper(II) acetate provides pyrimido[1,2-*c*][1,3]benzoxazine or pyrimido[1,2-*c*]quinazoline in one or two step(s) (Eq. 1, Scheme 1).¹⁸ Alternatively, addition of 2-(2-halophenyl)-1,4,5,6-tetrahydropyrimidine to carbon disulfide, isocyanate, or isothiocyanate, and subsequent aromatic nucleophilic substitution (S_NAr) affords pyrimidobenzothiazines and -oxazines, and pyrimidoquinazolines (Eq. 2, Scheme 1).¹⁹ The derivatives obtained from these reactions were easily converted to the pyrimido[1,2-*c*][1,3]benzothiazin-6-imine scaffold. Our two synthetic methods provide a variety of PD 404182 derivatives from the corresponding benzaldehydes in a few steps and in good yields, facilitating the lead optimization process.²⁰ In this article, a SAR study of PD 404182 derivatives using these synthetic approaches is described.

Results and discussion

Strategy for the SAR study of PD 404182

PD 404182 consists of three components, namely a 1,3-thiazin-2-imine core, and left-fused benzene and cyclic amidine moieties (Figure 2). In order to obtain detailed insights into the relationships between the compound structure and anti-HIV activity, we planned to investigate substituent effects on each component: (I) derivatives with various heteroatom (N, S, and O) arrangements on the 1,3-thiazin-2-imine core (Figure 2); (II) pyrimido[1,2-*c*][1,3]thiazin-6-imine derivatives fused with a substituted benzene ring or a five- or six-membered aromatic heterocycle; and (III) benzo[*e*][1,3]thiazin-2-imine derivatives fused with a cyclic amidine ring with or without accessory alkyl or aryl groups.

Synthesis of pyrimido[1,2-*c*][1,3]benzothiazin-6-imines and related tricyclic heterocycles

Our investigation began with the synthesis of tricyclic heterocycles with different combinations of heteroatoms on the 1,3-thiazin-2-imine core. Previously, we reported syntheses of pyrimido[1,2-*c*][1,3]benzoxazine and pyrimido[1,2-*c*]quinazoline derivatives using copper(II)-mediated C–H functionalization;¹⁸ this facilitates the introduction of oxygen or nitrogen functional groups at the *ortho*-position of 2-phenyl-1,4,5,6-tetrahydropyrimidine (**5**). Using compound **5** as a key starting material, a divergent approach was used for the preparation of a series of scaffolds (Scheme 2).

A one-pot reaction for Cu(OAc)₂-mediated C–H functionalization of **5** and subsequent treatment with triphosgene provided a 1,3-oxazin-2-one derivative **7** (Scheme 2). The same one-pot procedure using thiophosgene produced a trace amount of the desired thiocarbonyl derivative **8**; treatment of the purified intermediate **6** with thiophosgene provided the desired 1,3-oxazin-2-thione **8** in high yield. 1,3-Oxazin-2-imine **9** was obtained by the reaction of **6** with BrCN.

The copper-mediated C–N bond formation of compound **5** with *tert*-butylcarbamate followed by spontaneous intramolecular cyclization afforded a pyrimido[1,2-*c*]quinazolin-6-one scaffold **10**,

as demonstrated in our previous report (Scheme 2).¹⁸ Subsequent treatment with Lawesson's reagent led to formation of the thiocarbonyl derivative **11**. Since no hydrolysis of the carbonyl or thiocarbonyl group of compound **10** or **11** for construction of the 2-aminoquinazoline structure in **12** occurred, an alternative approach starting from 2-aminobenzyl alcohol **15** was used for the synthesis of the 2-aminoquinazoline derivative **12** (Scheme 3). After protection and PCC oxidation of **15**, oxidative amidination²¹ provided 2-(*p*-tosylamino)phenyltetrahydropyrimidine **17**. Deprotection followed by BrCN-mediated cyclization of **17** provided the expected 2-aminoquinazoline derivative **12**.

For the synthesis of pyrimido[1,2-*c*][1,3]benzothiazine derivatives, we adapted the C–H functionalization reaction for C–S bond formation (Scheme 2). After optimization of the reaction conditions, we found that exposure of compound **5** to CS₂ in the presence of Cu(OAc)₂ directly afforded a pyrimido[1,2-*c*][1,3]benzothiazine-6-thione scaffold **13**. Hydrolysis of the thiocarbonyl group in **13** followed by treatment with BrCN or triphosgene provided 6-imino or 6-oxo derivatives (**4** or **14**), respectively.

Synthesis of pyrimido[1,2-*c*][1,3]thiazine derivatives with fused benzene and heterocycles

Pyrimido[1,2-*c*][1,3]thiazin-6-imine derivatives **28–30** with a series of fused ring systems were prepared by consecutive heterocumulene addition and S_NAr reactions (Scheme 4).¹⁹ These reactions provide easy access to the construction of the 1,3-thiazin-2-imine derivatives and are more efficient than the diversity-oriented C–H functionalization approach. The oxidative amidination of aromatic aldehydes **18–20** with an accessory functional group afforded the corresponding 2-phenyltetrahydropyrimidine derivatives **21–23**. The pyrimido[1,2-*c*][1,3]thiazine-6-thione scaffold **24** was obtained by additions of **21f,g,i** or **23s,t,u** to carbon disulfide followed by S_NAr-type C–S bond formation. The desired 6-imino derivatives **28f,g,i** and **30s,t,u** were obtained via hydrolysis of the thiocarbonyl group of **24** followed by BrCN treatment. Alternatively, reactions of other 2-phenyltetrahydropyrimidines **21–23** with *tert*-butyl isothiocyanate afforded *N*-(*t*-Bu)-protected

thiazinimine derivatives **25–27**, which were treated with TFA to provide the expected products **28–30**.

The intermediates **25e**, **25k**, and **26k** were subjected to further manipulations to obtain the functionalized derivatives (Scheme 5). The nitro group of **25e** was reduced by hydrogenation to form the 9-amino derivative **31**. Alkylation of **31** afforded the 9-(*N*-methylamino) derivative **25b** (Eq. 1, Scheme 5). The 9-acetamide derivative **25c** was obtained by treatment of **31** with acetic anhydride (Eq. 2, Scheme 5). Sandmeyer reaction of **31** gave the 9-azide derivative **25p** (Eq. 3, Scheme 5). Me₂N- and MeO-substituted derivatives (**25a**, **26a**, and **26f**) were obtained by Me₂NH-mediated *N*-arylation²² of the 9-bromo **25k** and 10-bromo derivatives **26k**, and NaOMe-mediated Ullmann coupling²³ of **26k**, respectively (Eq. 4 and 7, Scheme 5). The 9-acetyl derivative **25d** was obtained by Heck reaction²⁴ of **25k** with 2-hydroxyethyl vinyl ether (Eq. 5, Scheme 5). Other derivatives with a variety of functional groups (**25h,l-o,q** and **26l,m,q**) were synthesized by Suzuki–Miyaura coupling reactions²⁵ of **25k** and **26k** with boronic acids or their pinacol esters (Eq. 6 and 7, Scheme 5). Final deprotection of the *tert*-butyl group in **25** and **26** afforded the 9- or 10-substituted pyrimido[1,2-*c*][1,3]benzothiazine derivatives **28** and **29**, respectively.

Synthesis of benzo[*e*][1,3]thiazine derivatives with fused cyclic amidines

Benzo[*e*][1,3]thiazine derivatives with various ring-sized and/or modified cyclic amidine moieties **35** were also synthesized by the consecutive heterocumulene addition and S_NAr reactions (Scheme 6). Oxidative amidination using several diamines **32** proceeded efficiently to form five- or six-membered rings (**33a–d**). The same reaction for the seven-membered amidine (**33e**) was incomplete, but purification of the Boc-protected amidine **36** followed by subsequent deprotection of the Boc group gave the pure seven-membered amidine **33e**. The resulting amidines were converted to cyclic-amidine-fused benzo[*e*][1,3]thiazin-2-imines **34** via *tert*-butyl isothiocyanate addition and an S_NAr reaction. TFA-mediated deprotection gave the expected derivatives **35**.

Structure-activity relationships of the central heterocyclic core in pyrimido[1,2-*c*][1,3]benzothiazines

Initially, the structural requirements of the 1,3-thiazin-2-imine core substructure in **4** (PD 404182) for anti-HIV activity were investigated (Table 1). The antiviral activities against the HIV-1_{IIIB} strain were evaluated using the MAGI assay. Substitution of the imino group in **4** with a carbonyl group (**14**) resulted in a significant decrease in anti-HIV activity ($EC_{50} = 8.94 \mu\text{M}$). Pyrimido[1,2-*c*][1,3]benzoxazines (**7–9**), pyrimido[1,2-*c*]quinazolines (**10–12**), and pyrimido[1,2-*c*][1,3]benzothiazine-6-thione (**13**), in which the 1-sulfur and/or 2-imino groups in **4** were modified, showed no activity. These results suggested that both the 1-sulfur atom and the 2-imino group are indispensable functional groups for the inhibitory activity against HIV infection, and may be involved in potential interactions with the target molecules.

Structure-activity relationships of the benzene substructure in pyrimido[1,2-*c*][1,3]benzothiazine

A series of derivatives with modification of the benzene substructure in the pyrimido[1,2-*c*][1,3]benzothiazine were evaluated for anti-HIV activity (Table 2). The addition of positively charged *N,N*-dimethylamino (**28a**) and *N*-methylamino groups (**28b**) at the 9-position significantly decreased the anti-HIV activity. The 9-acetamide group (**28c**), which has hydrogen-bond donor/acceptor abilities, also attenuated the bioactivity. The acetyl (**28d**) and nitro (**28e**) groups, with hydrogen acceptor properties, induced slight decreases in the anti-HIV activity. In contrast, derivatives with less-polarized substituents (**28f–o** and **28q**) at this position generally reproduced the potent anti-HIV activity of **4**. In terms of the electron-donating or -withdrawing properties of the substituent groups on the benzene substructure, good correlations were not observed. For example, the electron-donating methoxy (**28f**), methyl (**28g**), and *n*-butyl groups (**28h**), and the electron-withdrawing fluoro (**28i**) and trifluoromethyl groups (**28j**) exhibited similar anti-HIV activities ($EC_{50} = 0.44 - 0.57 \mu\text{M}$), indicating that the antiviral activity is independent of the

electronic state of the 1,3-benzothiazin-2-imine core in forming potential π -stacking interaction(s) with the target molecules. Among the hydrophobic substituents at this position, bromo (**28k**), phenyl (**28l**), vinyl (**28m**), styryl (**28n**), and pentenyl groups (**28o**) induced inhibitory activity two or three times greater than that of **4** ($EC_{50} = 0.18 - 0.25 \mu M$). Modification with photoreactive azido (**28p**) and benzoylphenyl groups (**28q**) maintained the inhibitory activity; these could be used as probe molecules to identify the target molecule(s) of **4**.²⁶

Similar SARs were observed for modification at the 10-position of pyrimido[1,2-*c*][1,3]benzothiazine. Addition of positively charged *N,N*-dimethylamino (**29a**) and polarized nitro groups (**29e**) reduced the anti-HIV activity ($EC_{50} = 2.12$ and $3.00 \mu M$, respectively). Hydrophobic groups including methoxy (**29f**), methyl (**29g**), bromo (**29k**), phenyl (**29l**), vinyl (**29m**), and 4-benzoylphenyl (**29q**) ($EC_{50} = 0.24 - 0.67 \mu M$) had favorable effects on the bioactivity, suggesting potential hydrophobic interactions of these additional functional groups with the target molecule(s).

Further miscellaneous modifications of benzothiazine substructure were also investigated (Table 2). The naphtho[2,3-*e*][1,3]thiazine derivative **30r**, with a 9,10-fused benzene, exhibited anti-HIV activity equipotent to that of the parent **4** ($EC_{50} = 0.56 \mu M$). A 6-fold decrease in the anti-HIV activity of the pyridine-fused pyrido[3,2-*e*][1,3]thiazine derivative (**30s**) was observed ($EC_{50} = 2.55 \mu M$). In addition, introduction of 8-bromo (**30k**) and 8,9-fused benzene (**30t**, naphtho[2,1-*e*][1,3]thiazine) substituents on benzothiazine resulted in a loss of activity, suggesting that modification at the 8-position was inappropriate for favorable interactions with the target molecule(s). The 11-fluoro derivative **30i** and thiophene-fused **30u**, which has a 5-6-6 framework (thieno[2,3-*e*][1,3]thiazine), exhibited four times lower and no inhibitory potencies, respectively.

Structure-activity relationships of cyclic amidine part of pyrimido[1,2-*c*][1,3]benzothiazine

A SAR study of the top-right cyclic amidine substructure was carried out. The five-membered dihydroimidazole derivative **35a** had no anti-HIV activity (Table 3), suggesting that the

five-membered ring may impair the critical interactions with the target molecule(s) via its small-sized ring strain or indirect effects on the thiazinimine core with a possibly altered conformation. Similarly, compound **35b** with the phenyl-fused dihydropyrimidine substructure showed lower inhibitory activity ($EC_{50} = 3.78 \mu\text{M}$). Appending one or two methyl groups on the six-membered pyrimidine (**35c** and **35d**) induced 1.5- to 2-fold higher inhibitory potencies ($EC_{50} = 0.35$ and $0.24 \mu\text{M}$, respectively) compared with that of the parent compound **4**. In addition, compound **35e** with a seven-membered tetrahydro-1,3-diazepine substructure exhibited similar anti-HIV activity to that of **4** ($EC_{50} = 0.31 \mu\text{M}$).

Mechanistic studies of anti-HIV pyrimido[1,2-*c*][1,3]benzothiazin-6-imines and related tricyclic heterocycles

To investigate the mechanism of action of PD 404182 derivatives, a time of drug addition study was carried out (Figure 3). In this experiment, the anti-HIV activity profiles of **4**²⁷ and its derivatives **29k**²⁷ were compared with those of well-known anti-HIV agents such as an adsorption inhibitor (DS 5000),²⁸ fusion inhibitor [enfuvirtide (T-20)],⁵ NRTI (AZT),²⁹ NNRTI (nevirapine),³⁰ and integrase inhibitor (raltegravir).⁶ After inoculation of HeLa-CD4/CCR5-LTR/ β -gal cells with HIV-1_{IIIB}, each anti-HIV-1 drug was added at a 90% inhibitory effect concentration at the indicated time points. The inhibitory effects on the infection were determined by counting the blue cells 48 h later. This investigation revealed that compound **4** (PD 404182) had an inhibitory profile in the early stage of viral infection similar to those of DS 5000 and enfuvirtide (Figure 3). Identical profiles were observed for derivative **29k**.

To gain additional insights into the mechanism of action of PD 404182 derivatives, the antiviral activities against other HIV subtypes were evaluated (Table 4). Compound **4** was effective against not only HIV-1_{IIIB} but also other two HIV-1 strains (HIV-1_{NL4-3} and HIV-1_{BaL}) with similar potency. Both HIV-1_{IIIB} and HIV-1_{NL4-3} strains utilize CXCR4 as a coreceptor for entry, while HIV-1_{BaL} strain does CCR5, indicating that chemokine receptors CXCR4 and CCR5 are not the

molecular targets of PD 404182 derivatives. The similar level of antiviral activity of **4** against HIV-2 (HIV-2_{EHO} and HIV-2_{ROD}), which is mainly distributed in West Africa, was observed. Highly potent inhibitory activities of a derivative **35d**²⁷ against these HIV strains were observed, as in the case of the SAR study of the HIV-1_{IIIB} strain discussed above. It has been well known that NNRTIs are not effective against HIV-2, highlighting that PD 404182 derivatives do not act as NNRTIs. Although PD 404182 derivatives and enfuvirtide showed similar anti-HIV-1 profile in the time of drug addition assay, HIV-2_{EHO} and HIV-2_{ROD} infection were affected by PD 404182 derivatives, in contrast with the less effective enfuvirtide,³¹ suggesting that PD 404182 derivatives may not be directed at the HIV gp41 envelope protein. Recent reports have suggested that the antiviral activities of compound **4** against HIV, HCV, and pseudotype lentiviruses were derived from disruption of the structural integrities of virions.¹⁷ Although the mechanism of action of PD 404182 derivatives is not fully understood at this stage, the unidentified biomolecule(s) in viruses or host cells, including envelope protein(s), lipid membranes and/or sugar chain(s), could be promising molecular targets for this new class of anti-HIV agents.

Conclusion

In conclusion, we have designed and synthesized PD 404182 derivatives for a novel series of anti-HIV agents. Comprehensive SAR studies demonstrated that the 6-6-6 fused pyrimido[1,2-*c*][1,3]benzothiazine scaffold and the heteroatom arrangement in the thiazinimine moiety are indispensable for the inhibitory activity of **4** (PD 404182) against HIV infection. Optimization studies of the benzene and cyclic amidine rings indicate that the introduction of a hydrophobic group on the benzene ring and the amidine group is more effective in improving the antiviral activity, giving potential favorable interaction(s) with the target molecule(s). In addition, PD 404182 derivatives could be promising agents for treatment of HIV-2 infection. We also revealed, using time of drug addition experiments, that PD 404182 derivatives prevent the HIV infection process at an early stage. For iterative molecular design of more effective derivatives based on

binding modes, the identification of the target molecule(s) of PD 404182 derivatives is being investigated using derivatives such as **28p** and **28q**.

Experimental section

General

¹H NMR spectra were recorded using a JEOL AL-400 or a JEOL ECA-500 spectrometer. Chemical shifts are reported in δ (ppm) relative to Me₄Si as an internal standard. ¹³C NMR spectra were referenced to the residual solvent signal. Exact mass (HRMS) spectra were recorded on a JMS-HX/HX 110A mass spectrometer. Melting points were measured by a hot stage melting point apparatus (uncorrected). For flash chromatography, Wakogel C-300E (Wako) or aluminium oxide 90 standardized (Merck) were employed. For preparative TLC, TLC Silica gel 60 F₂₅₄ (Merck), TLC Aluminium oxide 60 F₂₅₄ basic (Merck), or NH₂ Silica Gel 60 F₂₅₄ Plate (Wako) were employed. For analytical HPLC, a Cosmosil 5C18-ARII column (4.6 × 250 mm, Nacalai Tesque, Inc., Kyoto, Japan) was employed with method A [a linear gradient of CH₃CN containing 0.1% (v/v) TFA] or method B [a linear gradient of CH₃CN containing 0.1% (v/v) NH₃] at a flow rate of 1 cm³ min⁻¹ on a Shimadzu LC-10ADvp (Shimadzu Corp., Ltd., Kyoto, Japan), and eluting products were detected by UV at 254 nm. The purity of the compounds was determined by combustion analysis or HPLC analysis as >95% unless otherwise stated.

General procedure of oxidative amidination: synthesis of 2-(3-bromo-2-fluorophenyl)-1,4,5,6-tetrahydropyrimidine (23k). To a solution of 3-bromo-2-fluorobenzaldehyde **20k** (0.71 g, 3.5 mmol) in *t*-BuOH (33 cm³) was added propylenediamine (285.4 mg, 3.9 mmol). The mixture was stirred at 70 °C for 30 min, and then K₂CO₃ (1.45 g, 10.5 mmol) and I₂ (1.11 g, 4.4 mmol) were added. After being stirred at same temperature for 3 h, the mixture was quenched with sat. Na₂SO₃. The organic layer was separated and concentrated. The resulting solid was dissolved in H₂O, and then pH was adjusted to 12–14 with

2N NaOH. The whole was extracted with CHCl₃. The extract was dried over MgSO₄. After concentration, the resulting solid was recrystallized from CHCl₃–*n*-hexane to give compound **23k** as colorless crystals (0.62 g, 69%): mp 99 °C; IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 1624 (C=N); δ_{H} (400 MHz; CDCl₃; Me₄Si) 1.84–1.89 (2H, m, CH₂), 3.50 (4H, t, J = 5.7 Hz, 2 × CH₂), 5.13 (1H, br s, NH), 7.03 (1H, td, J = 8.0, 0.9 Hz, Ar), 7.54 (1H, ddd, J = 8.0, 6.4, 1.3 Hz, Ar) and 7.69 (1H, ddd, J = 8.0, 6.5, 1.3 Hz, Ar). δ_{C} (100 MHz; CDCl₃) 20.6, 42.1 (2C), 109.6 (d, J = 22.3 Hz), 125.1 (d, J = 4.1 Hz), 126.3 (d, J = 13.2 Hz), 129.8 (d, J = 3.3 Hz), 134.3, 150.8 and 156.3 (d, J = 248.3 Hz); δ_{F} (500 MHz; CDCl₃) –110.7; *Anal.* Calc. for C₁₀H₁₀BrFN₂: C, 46.72; H, 3.92; N, 10.90. Found: C, 46.64; H, 4.10; N, 10.93.

General procedure of CS₂-mediated cyclization for pyrimido[1,2-*c*][1,3]benzothiazine-6-thiones 24: synthesis of 3,4-dihydro-2*H*,6*H*-pyrimido[1,2-*c*]thieno[2,3-*e*][1,3]thiazin-6-thione (24u). To a mixture of 2-(3-bromothiophen-2-yl)-1,4,5,6-tetrahydropyrimidine **23u** (122.6 mg, 0.50 mmol) and NaH (40.0 mg, 1.0 mmol; 60% oil suspension) in DMF (1.7 cm³) was added CS₂ (0.060 cm³, 1.0 mmol) under an Ar atmosphere. After being stirred at 80 °C for 12 h, the mixture was concentrated. The residue was purified by flash chromatography over silica gel with *n*-hexane–EtOAc (8:2) to give the compound **24u** as pale yellow solid (80.5 mg, 67%): mp 167 °C (from CHCl₃–*n*-hexane); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 1624 (C=N); δ_{H} (400 MHz; CDCl₃; Me₄Si) 2.04–2.10 (2H, m, CH₂), 3.68 (2H, t, J = 5.5 Hz, CH₂), 4.42 (2H, t, J = 6.1 Hz, CH₂), 6.76 (1H, d, J = 5.4 Hz, Ar) and 7.49 (1H, d, J = 5.4 Hz, Ar). δ_{C} (100 MHz; CDCl₃) 21.5, 45.0, 48.5, 122.3, 128.4, 130.8, 131.0, 141.7 and 189.7; HRMS (FAB): m/z Calc. for C₉H₉N₂S₃ [M + H]⁺ 240.9928; found: 240.9936.

General procedure of *t*-BuNCS-mediated cyclization for *t*-Bu protected pyrimido[1,2-*c*][1,3]thiazin-6-imines 25–27, and 34: synthesis of *N*-*tert*-Butyl-3,4-dihydro-9-nitro-2*H*,6*H*-pyrimido[1,2-*c*][1,3]benzothiazin-6-imine (25e). To a

mixture of 2-(2-fluoro-4-nitrophenyl)-1,4,5,6-tetrahydropyrimidine **21e** (2.0 g, 8.96 mmol) and NaH (716.8 mg, 17.92 mmol; 60% oil suspension) in DMF (29.8 cm³) was added *t*-BuNCS (2.28 cm³, 17.92 mmol) under an Ar atmosphere. After being stirred at -20 °C to rt for 2 days, EtOAc was added. The resulting solution was washed with sat. NaHCO₃, brine, and dried over MgSO₄. After concentration, the residue was purified by flash chromatography over aluminum oxide with *n*-hexane–EtOAc (10:0 to 9:1) to give compound **25e** as pale yellow solid (1.77 g, 62%): mp 152–153 °C (from CHCl₃–*n*-hexane); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 1604 (C=N), 1591 (NO₂), 1581 (C=N), 1523 (NO₂); δ_{H} (500 MHz; CDCl₃; Me₄Si) 1.39 (9H, s, 3 × CH₃), 1.91–1.96 (2H, m, CH₂), 3.66 (2H, t, *J* = 5.2 Hz, CH₂), 3.88 (2H, t, *J* = 5.7 Hz, CH₂), 7.97 (2H, dd, *J* = 9.7, 2.3 Hz, Ar), 8.01 (2H, d, *J* = 2.3 Hz, Ar) and 8.39 (1H, d, *J* = 9.2 Hz, Ar). δ_{C} (125 MHz; CDCl₃) 21.7, 30.0, 45.3, 45.5, 54.5, 119.9, 120.3, 130.0, 131.1, 132.8, 136.1, 146.5 and 148.5; HRMS (FAB): *m/z* Calc. for C₁₅H₁₉N₄O₂S [M + H]⁺ 319.1229; found: 319.1229.

General procedure of BrCN-mediated cyclization for pyrimido[1,2-*c*][1,3]thiazin-6-imines **28 and **30**: synthesis of 3,4-dihydro-9-methyl-2*H*,6*H*-pyrimido[1,2-*c*][1,3]benzothiazin-6-imine (**28g**).** 3,4-Dihydro-9-methyl-2*H*-pyrimido[1,2-*c*][1,3]benzothiazine-6-thione **24g** (62.1 mg, 0.25 mmol) was suspended into a 0.1M solution of NaOH in MeOH/H₂O (9:1) (5 cm³). After being stirred for 12 h under reflux, the mixture was concentrated. The residue was suspended in anhydrous EtOH (1 cm³) and BrCN (53.0 mg, 0.50 mmol) was added under Ar atmosphere. After stirring for 2 h under reflux, the reaction mixture was quenched with 2N NaOH. The whole was extracted with CHCl₃, and dried over MgSO₄. After concentration, the residue was purified by flash chromatography over aluminum oxide with *n*-hexane–EtOAc (9:1) to give the compound **28g** as colorless solid (39.2 mg, 68%): mp 121 °C (from CHCl₃–*n*-hexane); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 1620 (C=N), 1569 (C=N); δ_{H} (500 MHz; CDCl₃; Me₄Si) 1.94–1.99 (2H, m, CH₂), 2.32 (3H, s, CH₃), 3.67 (2H, t, *J* = 5.7 Hz, CH₂), 4.01 (2H, t, *J* = 6.3 Hz, CH₂), 6.84 (1H, s, Ar), 7.02 (1H, d, *J* = 8.6 Hz, Ar), 7.16 (1H, br s, NH) and 8.10 (1H, d, *J* = 8.6 Hz, Ar). δ_{C} (125 MHz; CDCl₃) 21.1, 21.1, 43.8, 44.9, 123.6, 124.1, 127.4, 128.6,

128.8, 141.1, 146.6 and 153.6; HRMS (FAB): m/z Calc. for $C_{12}H_{14}N_3S$ $[M + H]^+$ 232.0908; found: 232.0912.

General procedure of *tert*-butyl deprotection for pyrimido[1,2-*c*][1,3]benzothiazin-6-imines 28-30: synthesis of 3,4-dihydro-9-nitro-2*H*,6*H*-pyrimido[1,2-*c*][1,3]benzothiazin-6-imine (28e). TFA (1.5 cm³) was added to a mixture of *N*-(*tert*-butyl)-3,4-dihydro-9-nitro-2*H*, pyrimido[1,2-*c*][1,3]benzothiazin-6-imine **25e** (47.8 mg, 0.15 mmol) in CHCl₃ and molecular sieves 4Å (225 mg, powder, activated by heating with Bunsen burner). After being stirred under reflux for 1.5 h, the mixture was concentrated. To a mixture of this residue in CHCl₃ was added dropwise Et₃N at 0 °C to adjust pH to 8–9. The whole was extracted with EtOAc, and the extract was washed with sat. NaHCO₃, brine, and dried over MgSO₄. After concentration, the residue was purified by flash chromatography over aluminum oxide with *n*-hexane–EtOAc (19:1 to 1:1) to give compound **28e** as pale yellow solid (24.9 mg, 63%): mp 170–172 °C (from CHCl₃–*n*-hexane); IR (neat) $\nu_{\max}/\text{cm}^{-1}$: 1620 (C=N), 1587 (NO₂), 1568 (C=N), 1523 (NO₂); δ_{H} (400 MHz; CDCl₃; Me₄Si) 1.97–2.03 (2H, m, CH₂), 3.74 (2H, t, J = 5.6 Hz, CH₂), 4.04 (2H, t, J = 6.2 Hz, CH₂), 7.41 (1H, br s, NH), 7.93 (1H, d, J = 2.2 Hz, Ar), 8.00 (1H, dd, J = 9.0, 2.2 Hz, Ar) and 8.42 (1H, d, J = 9.0 Hz, Ar). δ_{C} (100 MHz; CDCl₃) 20.8, 43.8, 45.2, 118.9, 120.5, 130.4, 130.8, 131.7, 145.1, 148.7 and 151.3; *Anal.* Calc. for C₁₁H₁₀N₄O₂S: C, 50.37; H, 3.84; N, 21.36. Found: C, 50.29; H, 4.03; N, 21.08.

General procedure of Suzuki-Miyaura cross coupling for 9-aryl pyrimido[1,2-*c*][1,3]thiazine derivatives: synthesis of *N*-*tert*-butyl-9-phenyl-3,4-dihydro-2*H*,6*H*-pyrimido[1,2-*c*][1,3]benzothiazin-6-imine 25l. To a solution of *N*-(*tert*-butyl)-3,4-dihydro-9-bromo-2*H*,6*H*-pyrimido[1,2-*c*][1,3]benzothiazin-6-imine **25k** (52.8 mg, 0.15 mmol) and phenylboronic acid (21.9 mg, 0.18 mmol) in a mixture of toluene (1.5 cm³), EtOH (0.9 cm³) and 1M aq. K₂CO₃ (1.5 cm³) was added Pd(PPh₃)₄ (6.9 mg, 4 mol%) and

PdCl₂(dppf)·CH₂Cl₂ (3.67 mg, 3 mol%). After being stirred at reflux for 1 h, the mixture was extracted with CHCl₃. The organic layers were dried over MgSO₄ and concentrated. The residue was purified by flash chromatography over aluminum oxide with *n*-hexane–EtOAc (10:0 to 9:1) to give the compound **25I** as colorless solid (44.8 mg, 85%): mp 122.5–124 °C (from CHCl₃–*n*-hexane); IR (neat) $\nu_{\text{max}}/\text{cm}^{-1}$: 1592 (C=N); δ_{H} (500 MHz; CDCl₃; Me₄Si) 1.40 (9H, s, 3 × CH₃), 1.90-1.95 (2H, m, CH₂), 3.64 (2H, t, *J* = 5.4 Hz, CH₂), 3.89 (2H, t, *J* = 6.0 Hz, CH₂), 7.33-7.37 (2H, m, Ar), 7.41-7.44 (3H, m, Ar), 7.58 (2H, d, *J* = 6.9 Hz, Ar) and 8.25 (1H, d, *J* = 8.6 Hz, Ar). δ_{C} (125 MHz; CDCl₃) 21.9, 30.0 (3C), 45.1, 45.4, 54.2, 122.7, 124.8, 126.5, 127.0 (2C), 128.0, 128.8 (2C), 128.9, 129.5, 138.3, 139.4, 142.9 and 147.7; HRMS (FAB): *m/z* Calc. for C₂₁H₂₄N₃S [M + H]⁺ 350.1691; found: 350.1683.

Determination of anti-HIV activity

The sensitivity of three HIV-1 strains and two HIV-2 strains was determined by the MAGI assay.³² The target cells (HeLa-CD4/CCR5-LTR/β-gal; 104 cells/well) were plated in 96-well flat microtiter culture plates. On the following day, the cells were inoculated with the HIV-1 (60 MAGI U/well, giving 60 blue cells after 48 h of incubation) and cultured in the presence of various concentrations of the drugs in fresh medium. Forty-eight hours after viral exposure, all the blue cells stained with X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) were counted in each well. The activity of test compounds was determined as the concentration that blocked HIV-1 infection by 50% (50% effective concentration [EC₅₀]). EC₅₀ was determined by using the following formula:

$$\text{EC}_{50} = 10^{\left[\log(A/B) \times (50 - C)/(D - C) + \log(B)\right]},$$

wherein

A: of the two points on the graph which bracket 50% inhibition, the higher concentration of the test compound,

B: of the two points on the graph which bracket 50% inhibition, the lower concentration of the test compound,

C: inhibitory activity (%) at the concentration B,

D: inhibitory activity (%) at the concentration A.

Acknowledgements

We are indebted to Dr. Hideki Maeta, Dr. Masahiko Taniguchi, Mr. Takayuki Kato, Ms. Kumiko Hiyama, Mr. Shuhei Osaka, Dr. Megumi Okubo, Dr. Daisuke Nakagawa, Mr. Tatsuya Murakami, and Dr. Kazunobu Takahashi for excellent technical assistance. This work was supported by Grants-in-Aid for Scientific Research and Targeted Protein Research Program from MEXT and Health and Labor Science Research Grants (Research on HIV/AIDS, Japan). T. M. is grateful for JSPS Research Fellowships for Young Scientists.

References and notes

1. J. A. Esté and T. Cihlar, *Antiviral Res.*, 2010, **85**, 25.
2. P. G. Yeni, S. M. Hammer, C. C. J. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella and P. A. Volberding, *JAMA*, 2002, **288**, 222.
3. V. A. Johnson, V. Calvez, H. F. Günthard, R. Paredes, D. Pillay, R. Shafer, A. M. Weinsing and D. D. Richman, *Top. Antivir. Med.*, 2011, **19**, 156.
4. A. Carr and D. A. Cooper, *Lancet*, 2000, **356**, 1423.
5. (a) B. A. Larder and S. D. Kemp, *Science*, 1989, **246**, 1155; (b) P. Kellam, C. A. B. Boucher and B. A. Larder, *Proc. Natl. Acad. Sci. U.S.A.*, 1992, **89**, 1934; (c) D. J. Hooker, G. Tachedjian, A. E. Solomon, A. D. Gurusinghe, S. Land, C. Birch, J. L. Anderson, B. M. Roy, E. Arnold and N. J. Deacon, *J. Virol.*, 1996, **70**, 8010; (d) E. P. Coakley, J. M. Gillis and S. M. Hammer, *AIDS*, 2000, **14**, F9; (e) V. Miller and B. A. Larder, *Antivir. Ther.*, 2001, **6**, 25.
6. E. Anuurad, A. Bremer and L. Berglund, *Curr. Opin. Endocrinol., Diabetes Obes.*, 2010, **17**, 478.

7. (a) J. M. Kilby and J. J. Eron, *N. Engl. J Med.*, 2003, **348**, 2228; (b) J. P. Lalezari, K. Henry, M. O'Hearn, J. S. Montaner, P. J. Piliero, B. Trottier, S. Walmsley, C. Cohen, D. R. Kuritzkes, J. J. Eron, Jr., J. Chung, R. DeMasi, L. Donatucci, C. Drobnes, J. Delehanty and M. Salgo, *N. Engl. J. Med.*, 2003, **348**, 2175; (c) T. Matthews, M. Salgo, M. Greenberg, J. Chung, R. DeMasi and D. Bolognesi, *Nat. Rev. Drug Discov.*, 2004, **3**, 215.
8. (a) B. Grinsztejn, B.-Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey and R. D. Isaacs, *Lancet*, 2007, **369**, 1261; (b) R. T. Steigbigel, D. A. Cooper, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. M. Gatell, J. K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, J. Zhao, J. Chen, D. M. Ryan, R. R. Rhodes, J. A. Killar, L. R. Gilde, K. M. Strohmaier, A. R. Meibohm, M. D. Miller, D. J. Hazuda, M. L. Nessly, M. J. DiNubile, R. D. Isaacs, B.-Y. Nguyen and H. Teppler, *N. Engl. J Med.*, 2008, **359**, 339.
9. (a) P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood and M. Perros, *Antimicrob. Agents Chemother.*, 2005, **49**, 4721; (b) G. Fätkenheuer, A. L. Pozniak, M. A. Johnson, A. Plettenberg, S. Staszewski, A. I. M. Hoepelman, M. S. Saag, F. D. Goebel, J. K. Rockstroh, B. J. Dezube, T. M. Jenkins, C. Medhurst, J. F. Sullivan, C. Ridgway, S. Abel, I. T. James, M. Youle and E. Van Der Ryst, *Nat. Med.*, 2005, **11**, 1170.
10. (a) A. R. Katritzky, S. R. Tala, H. Lu, A. V. Vakulenko, Q.-Y. Chen, J. Sivapackiam, K. Pandya, S. Jiang and A. K. Debnath, *J. Med. Chem.*, 2009, **52**, 7631. (b) S. Jiang, S. R. Tala, H. Lu, N. E. Abo-Dya, I. Avan, K. Gyanda, L. Lu, A. R. Katritzky and A. K. Debnath, *J. Med. Chem.*, 2011, **54**, 572.
11. G. Zhou, D. Wu, B. Snyder, R. G. Ptak, H. Kaur and M. Gochin, *J. Med. Chem.*, 2011, **54**, 7220.
12. (a) P.-F. Lin, W. S. Blair, T. Wang, T. P. Spicer, Q. Guo, N. Zhou, Y.-F. Gong, H.-G. H. Wang, R. Rose, G. Yamanaka, B. Robinson, C.-B. Li, R. Fridell, C. Deminie, G. Demers, Z. Yang, L. Zadajura, N. A. Meanwell and R. J. Colonno, *Proc. Natl. Acad. Sci. U.S.A.*, 2003, **100**, 11013; (b)

- Z. Si, N. Madani, J. M. Cox, J. J. Chruma, J. C. Klein, A. Schon, N. Phan, W. Wang, A. C. Biorn, S. Cocklin, I. Chaiken, E. Freire, A. B. Smith, J. G. Sodroski, *Proc. Natl. Acad. Sci U.S.A.*, 2004, **101**, 5036; (c) Q. Zhao, L. Ma, S. Jiang, H. Lu, S. Liu, Y. He, N. Strick, N. Neamati and A. K. Debnath, *Virology*, 2005, **339**, 213; (d) T. Wang, Z. Yin, Z. Zhang, J. A. Bender, Z. Yang, G. Johnson, Z. Yang, L. M. Zadjura, C. J. D'Arienzo, D. D. Parker, C. Gesenberg, G. A. Yamanaka, Y.-F. Gong, H.-T. Ho, H. Fang, N. Zhou, B. V. McAuliffe, B. J. Eggers, L. Fan, B. Nowicka-Sans, I. B. Dicker, Q. Gao, R. J. Colonno, P.-F. Lin, N. A. Meanwell and J. F. Kadow, *J. Med. Chem.*, 2009, **52**, 7778.
13. (a) A. Otaka, M. Nakamura, D. Nameki, E. Kodama, S. Uchiyama, S. Nakamura, H. Nakano, H. Tamamura, Y. Kobayashi, M. Matsuoka and N. Fujii, *Angew. Chem., Int. Ed.*, 2002, **41**, 2937; (b) N. Fujii, S. Oishi, K. Hiramatsu, T. Araki, S. Ueda, H. Tamamura, A. Otaka, S. Kusano, S. Terakubo, H. Nakashima, J. A. Broach, J. O. Trent, Z.-X. Wang and S. C. Peiper, *Angew. Chem., Int. Ed.*, 2003, **42** 3251; (c) S. Ueda, S. Oishi, Z.-X. Wang, T. Araki, H. Tamamura, J. Cluzeau, H. Ohno, S. Kusano, H. Nakashima, J. O. Trent, S. C. Peiper and N. Fujii, *J. Med. Chem.*, 2007, **50**, 192; (d) S. Oishi, S. Ito, H. Nishikawa, K. Watanabe, M. Tanaka, H. Ohno, K. Izumi, Y. Sakagami, E. Kodama, M. Matsuoka and N. Fujii, *J. Med. Chem.*, 2008, **51**, 388; (e) E. Inokuchi, S. Oishi, T. Kubo, H. Ohno, K. Shimura, M. Matsuoka and N. Fujii, *ACS Med. Chem. Lett.*, 2011, **2**, 477.
14. M. R. Birck, T. P. Holler and R. W. Woodard, *J. Am. Chem. Soc.*, 2000, **122**, 9334.
15. (a) B. P. Duckworth and C. C. Aldrich, *Anal. Biochem.*, 2010, **403**, 13; (b) T. L. Foley, A. Yasgar, C. J. Garcia, A. Jadhav, A. Simeonov and M. D. Burkart, *Org. Biomol. Chem.*, 2010, **8**, 4601.
16. K. Chockalingam, R. L. Simeon, C. M. Rice and Z. Chen, *Proc. Natl. Acad. Sci. U.S.A.*, 2010, **107**, 3764.
17. A. M. Chamoun, K. Chockalingam, M. Bobardt, R. Simeon, J. Chang, P. Gallay and Z. Chen, *Antimicrob. Agents Chemother.*, 2012, **56**, 672.
18. T. Mizuhara, S. Inuki, S. Oishi, N. Fujii and H. Ohno, *Chem. Commun.*, 2009, 3413.

19. T. Mizuhara, S. Oishi, N. Fujii and H. Ohno, *J. Org. Chem.*, 2010, **75**, 265.
20. In the previous reports, compound **4** was obtained via benzo-1,2-dithiole-3-thiones and 2-(1,4,5,6-tetrahydro-2-pyrimidinyl)benzenethiol in 3% yield from 2-chlorobenzylchloride, see:
 (a) H. Helmut, M. Juergen and Z. Hans, *Eur. Pat. Appl.*, 1982, EP 43936; (b) J. P. Brown, *J. Chem. Soc., Perkin Trans.*, 1974, **1**, 869; (c) S. Peter and S. Gerhard, *Ger. Offen.*, 1979, DE 2811131.
21. M. Ishihara and H. Togo, *Tetrahedron*, 2007, **63**, 1474.
22. (a) J. P. Wolfe, S. Wagaw, J.-F. Marcoux and S. L. Buchwald, *Acc. Chem. Res.*, 1998, **31**, 805;
 (b) J. P. Hartwig, *Angew. Chem., Int. Ed.*, 1998, **37**, 2046.
23. K. Kunz, U. Scholz and D. Ganzer, *Synlett*, 2003, 2428.
24. R. K. Arvela, S. Pasquini and M. Larhed, *J. Org. Chem.*, 2007, **72**, 6390.
25. (a) N. Miyaoura and A. Suzuki, *Chem. Rev.*, 1995, **95**, 2457; (b) A. Suzuki, *J. Organomet. Chem.*, 1999, **576**, 147.
26. (a) R. R. Drake, N. Neamati, H. Hong, A. A. Pilon, P. Sunthankar, S. D. Hume, G. W. A. Milne and Y. Pommier, *Proc. Natl. Acad. Sci. U.S.A.*, 1998, **95**, 4170; (b) W. Lin, K. Li and M. B. Doughty, *Bioorg. Med. Chem.*, 2002, **10**, 4131. (c) L. Q. Al-Mawsawi, V. Fikkert, R. Dayam, M. Witvrouw, T. R. Burke, Jr., C. H. Borchers and N. Neamati, *Proc. Natl. Acad. Sci. U.S.A.*, 2006, **103**, 10080.
27. The cytotoxicity of compounds **4**, **29k** and **35d** was not observed at 10 μ M in the MAGI assay. Further toxicity studies such as hemolytic activity or renal/liver accumulation may be needed to take a drug for long periods of time.
28. M. Baba, D. Scgols, R. Pauwels, H. Nakashima and E. De Clercq, *J. Acquir. Immune. Defic. Syndr.*, 1990, **3**, 493.
29. M. A. Fischl, D. D. Richman and M. H. Grieco, *N. Engl. J. Med.*, 1987, **317**, 185.
30. (a) V. J. Merluzzi, K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C.-K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosethal, R. Faanes, R. J. Eckner, R. A. Koup and J. L.

- Sullivan, *Science*, 1990, **250**, 1411; (b) M. Skoog, K. D. Hargrave, J. J. Miglietta, E. B. Kopp and V. J. Merluzzi, *Med. Res. Rev.*, 1992, **12**, 27.
31. M. Witvrouw, C. Pannecouque, W. M. Switzer, T. M. Folks, E. De Clercq and W. Heneine, *Antivir. Ther.*, 2004, **9**, 57.
32. K. Watanabe, S. Negi, Y. Sugiura, A. Kiriya, A. Honbo, K. Iga, E. N. Kodama, T. Naitoh, M. Matsuoka and Kano, K. *Chem. Asian J.*, 2010, **5**, 825.

Figure 1. Structures of newly reported anti-HIV compounds (**1–3**) targeting HIV-1 envelope proteins, and PD 404182 (**4**).




Figure 2. Strategy for SAR study of PD 404182 (**4**).








Figure 3. Time of drug addition profiles for infection by HIV-1_{IIIB} strain of HeLa-CD4/CCR5-LTR/ β -gal cells.




Scheme 1. Our synthetic methods for PD 404182 derivatives.




Scheme 2. Synthesis of PD 404182 derivatives with different combinations of heteroatoms. Reagents and conditions: (a) $\text{Cu}(\text{OAc})_2$, H_2O , O_2 , DMF, $130\text{ }^\circ\text{C}$, 69%; (b) triphosgene, TMEDA, CH_2Cl_2 , $0\text{ }^\circ\text{C}$ to rt, 70% [2 steps (a,b)]; (c) thiophosgene, Et_3N , CH_2Cl_2 , $0\text{ }^\circ\text{C}$ to rt, quant.; (d) BrCN , CH_2Cl_2 , rt, 34%; (e) $\text{Cu}(\text{OAc})_2$, BocNH_2 , O_2 , DMF, $130\text{ }^\circ\text{C}$, 53%; (f) Lawesson's reagent, xylene, reflux, 19%; (g) $\text{Cu}(\text{OAc})_2$, CS_2 , O_2 , 1,4-dioxane, $130\text{ }^\circ\text{C}$, 11%; (h) NaOH , MeOH , H_2O , reflux; (i) BrCN , EtOH , reflux, 61% [2 steps (h,i)]; (j) triphosgene, Et_3N , CH_2Cl_2 , $0\text{ }^\circ\text{C}$ to rt, 65% [2 steps (h,j)].




Scheme 3. Synthesis of 2-aminoquinazoline derivative **12**. Reagents and conditions: (a) *p*-TsCl, pyridine, CHCl₃, rt; (b) PCC, silica gel, CH₂Cl₂, rt, 80% [2 steps (a,b)]; (c) 1,3-propanediamine, I₂, K₂CO₃, *t*-BuOH, 70 °C, 98%; (d) conc. H₂SO₄, 100 °C, then NaOH, H₂O; (e) BrCN, EtOH, reflux, 66% [2 steps (d,e)].



Scheme 4. Synthesis of pyrimido[1,2-*c*][1,3]thiazin-6-imine derivatives fused with substituted benzene and heterocycles (**28–30**). Reagents and conditions: (a) 1,3-propanediamine, I₂, K₂CO₃, *t*-BuOH, 70 °C, 58-91%; (b) NaH, CS₂, DMF, 80 °C, 67%-quant.; (c) NaH or *t*-BuOK, *t*-BuNCS, DMF or DMAc, -20–80 °C, 28-95%; (d) (i) NaOH, MeOH, H₂O, reflux, (ii) BrCN, EtOH, reflux, 32-68%; (e) TFA, MS4Å, CHCl₃, reflux, 63-92%.



Scheme 5. Synthesis of 9- or 10-substituted pyrimido[1,2-*c*][1,3]benzothiazin-6-imine derivatives. Reagents and conditions: (a) H₂, Pd/C, EtOH, rt, 88%; (b) NaOMe, (CH₂O)_{*n*}, MeOH, reflux, then NaBH₄, 91%; (c) TFA, MS4Å, CHCl₃, reflux, 37-95%; (d) Ac₂O, DMAP, Et₃N, CH₂Cl₂, rt, quant.; (e) NaNO₂, AcOH, H₂O, 0 °C, then NaN₃, 70%; (f) Pd(OAc)₂, *t*-Bu₃P, NHMe₂, THF, KO*t*-Bu, toluene, reflux, quant.; (g) 2-hydroxyethylvinylether, Pd(OAc)₂, 1,3-bis(diphenylphosphino)propane, K₂CO₃, H₂O, 90 °C, 13% [2 steps (g,c)]; (h) R-B(OH)₂ or R-Bpin, Pd(PPh₃)₄, PdCl₂(dppf)·CH₂Cl₂, K₂CO₃, toluene or 1,4-dioxane, EtOH, H₂O, reflux, 62-96%; (i) *n*-BuB(OH)₂, Pd₂(dba)₃, P(*t*-Bu)₃, CsCO₃, 1,4-dioxane, reflux, 6% (for **25h**); (j) Pd(*Pt*-Bu)₂, NHMe₂, THF, KO*t*-Bu, toluene, 170 °C, 67% (for **26a**); (k) CuBr, NaOMe, MeOH, DMF, reflux, 40% (for **26f**).



Scheme 6. Synthesis of benzo[*e*][1,3]thiazine derivatives with fused cyclic amidines. Reagents and conditions: (a) 2-fluorobenzaldehyde or 2-bromobenzaldehyde, I₂, K₂CO₃, *t*-BuOH, 70 °C, 68-79%; (b) NaH, *t*-BuNCS, DMF, rt–80 °C, 18-50%; (c) TFA, MS4Å, CHCl₃, reflux, 16-86%; (d) Boc₂O, Et₃N, DMAP, CH₂Cl₂, rt, 37% [2 steps (a,d)]; (e) TFA, CH₂Cl₂, reflux, 80%.





Table 1. SARs for 1,3-thiazin-2-imine core.



compound	X	Y	EC ₅₀ (μM) ^a
4	S	NH	0.44 ± 0.08
7	O	O	>10
8	O	S	>10
9	O	NH	>10
10	NH	O	>10
11	NH	S	>10
12	NH	NH	>10
13	S	S	>10
14	S	O	8.94 ± 1.07


^a EC₅₀ values were the concentration that blocks HIV-1 infection by 50% and derived from three independent experiments.







Table 2. SARs for benzene part.

compound		EC ₅₀ (μM) ^a	compound		EC ₅₀ (μM) ^a
4	R = H	0.44 ± 0.08	30r		0.56 ± 0.13
28a	R = NMe ₂	4.74 ± 1.07			
28b	R = NHMe	>10	30s		2.55 ± 0.26
28c	R = NHAc	>10			
28d	R = COMe	1.44 ± 0.33	30k		>10
28e	R = NO ₂	1.13 ± 0.18			
28f	R = OMe	0.57 ± 0.09	30t		>10
28g	R = Me	0.49 ± 0.10			
28h	R = <i>n</i> -butyl	0.44 ± 0.09	30i		1.68 ± 0.19
28i	R = F	0.50 ± 0.07			
28j	R = CF ₃	0.53 ± 0.12	30u		>10
28k	R = Br	0.25 ± 0.09			
28l	R = Ph	0.24 ± 0.04			
28m	R = vinyl	0.18 ± 0.05			
28n	R = styryl	0.25 ± 0.05			
28o	R = pentenyl	0.24 ± 0.11			
28p	R = N ₃	0.43 ± 0.06			
28q	R = C ₆ H ₄ (4-Bz)	0.53 ± 0.12			
29a	R = NMe ₂	2.12 ± 0.26			
29e	R = NO ₂	3.00 ± 0.59			
29f	R = OMe	0.53 ± 0.04			
29g	R = Me	0.38 ± 0.04			
29k	R = Br	0.24 ± 0.05			
29l	R = Ph	0.24 ± 0.05			
29m	R = vinyl	0.40 ± 0.09			
29q	R = C ₆ H ₄ (4-Bz)	0.67 ± 0.16			

^a EC₅₀ values were the concentration that blocks HIV-1 infection by 50% and derived from three independent experiments.

Table 3. SARs for cyclic amidine.



compound		EC ₅₀ (μM) ^a
4		0.44 ± 0.08
35a		>10
35b		3.78 ± 1.39
35c		0.35 ± 0.09
35d		0.24 ± 0.04
35e		0.31 ± 0.06

^a EC₅₀ values were the concentration that blocks HIV-1 infection by 50% and derived from three independent experiments.

Table 4. Anti-HIV activity of **4** and **35d** against other HIV strains.

strains	EC ₅₀ (μM) ^a	
	4	35d
HIV-1 _{NL4-3}	0.38 ± 0.06	0.25 ± 0.03
HIV-1 _{BaL}	0.37 ± 0.06	0.16 ± 0.02
HIV-2 _{EHO}	0.31 ± 0.06	0.17 ± 0.03
HIV-2 _{ROD}	0.30 ± 0.06	0.11 ± 0.03

^a EC₅₀ values were the concentration that blocks HIV infection by 50% and derived from three independent experiments.